Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsBrivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibitionEvading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsAdipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokinesDynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel densityA PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancerEndothelial cell-derived interleukin-6 regulates tumor growth.Neutralizing endogenous VEGF following traumatic spinal cord injury modulates microvascular plasticity but not tissue sparing or functional recovery.Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceCD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancerDissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis.MR reporter gene imaging of endostatin expression and therapy.Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium.Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells.Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.The aortic ring model of angiogenesis: a quarter century of search and discovery.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients.NAADP-Dependent Ca(2+) Signaling Controls Melanoma Progression, Metastatic Dissemination and NeoangiogenesisGlioblastoma: Defining Tumor Niches.Enhanced angiogenesis, hypoxia and neutrophil recruitment during Myc-induced liver tumorigenesis in zebrafishRole of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapiesThe tumor microenvironment: the making of a paradigm.Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells.Controlling escape from angiogenesis inhibitors.Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.Regulation of CLL survival by hypoxia-inducible factor and its target genes.Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1.Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.A FGFR1 inhibitor patent review: progress since 2010.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.The inefficacy of antiangiogenic therapies.Metastatic gastric cancer - focus on targeted therapies.Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition.Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer.SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models.
P2860
Q21183974-40496A42-6D69-49F8-8703-F0B2C11D621EQ24616631-165C91C0-2B2E-4D02-9618-2364464BF8CFQ26773795-5852BFAB-88FB-49F0-9380-82DF4ADFF206Q27001148-69F2006A-020B-4FF8-B189-84788B8F466DQ27308856-B2387989-BAF4-42B0-AA8E-64EC4A4FE90CQ28485246-080A1A95-9C86-450A-8B39-87A183CA1A7AQ33592677-FF9456CC-8E50-4467-B818-68BA305E96B6Q33619010-FB395FC0-73DA-4A06-9A27-5354A0CD9024Q33627739-24A4C1FF-4E49-4A61-BDE3-ED92B434731CQ33630819-CB80BEB1-D890-4461-B453-4588E60E6F12Q34128953-22A7FE66-ADAA-40CB-9B18-A83393128192Q34141587-539E58F0-D613-4C40-8CC5-3A6CF2C751FCQ34383516-8FE51714-C1A1-44C3-A9D0-99F830CFADF5Q34547793-15F4C637-F3AF-4B7F-A1F9-A8B5BAD3260AQ34708917-8437BBE1-FEC5-4C29-952B-9A074E32F140Q35216301-42893229-2308-44FD-A1EB-DEDB868FEC57Q35832019-9E87BCC0-A455-4E7B-9DE9-9C1EAAC4FE92Q35837949-4756F287-11D9-4D20-B820-A6873D1479DFQ36089956-73C88C30-C6BE-46A0-8534-AC6B2219DED1Q36432462-542906BE-3ED6-48AD-BD94-9A4E86EB574AQ36796616-25FA760B-319E-40C5-8B2D-0467F2893D6FQ37195560-B2BB350F-4708-44BF-8217-04A59608880EQ37228059-8AEA3C29-3BF2-4ADD-8327-7AE69D058F63Q37373366-C1283555-ECA6-4456-A8AE-F0C3B273DB96Q37406706-A638D7DB-C812-4B7C-B455-C8FB723C50FBQ37589238-5A495CA5-A853-4C82-92AD-7BE5711598F9Q37672654-FE254BFA-AA89-4607-8352-1B2109D120F3Q37705932-6923B25D-D92F-49A2-8C3B-A0CE21F2C45CQ38030217-4514BF9B-EE35-4849-80BA-A56FF51E29CDQ38317180-444FE373-AC8A-4F11-8E30-3ADB89F11E22Q38325527-E8DE775F-DC17-4630-A5AE-649376266754Q38773966-671C1596-2D90-40C4-A765-40FF4B00C96BQ38782612-92232C7E-A585-4E19-A1C5-2F347E886BFBQ39008859-679DF255-C466-45E3-90AB-55621189657EQ39232954-CED7D2C6-4A3F-459D-B1D6-0D7FE1C37619Q41645968-B9503791-E4EA-40CB-A8BE-D288104CE1A6Q41907024-344DECDA-E0BF-482D-A755-DF756420CD63Q43184381-5392BED3-71EB-468B-B4BB-C6D8D33152E5Q44864734-6471AD2A-2FA9-4539-AEBE-329C3F17291DQ50107409-BEB37BA9-A65B-4E5C-879B-783B49896BB5
P2860
Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of the microenvironment i ...... to anti-angiogenic therapies.
@en
Role of the microenvironment i ...... to anti-angiogenic therapies.
@nl
type
label
Role of the microenvironment i ...... to anti-angiogenic therapies.
@en
Role of the microenvironment i ...... to anti-angiogenic therapies.
@nl
prefLabel
Role of the microenvironment i ...... to anti-angiogenic therapies.
@en
Role of the microenvironment i ...... to anti-angiogenic therapies.
@nl
P1476
Role of the microenvironment i ...... to anti-angiogenic therapies.
@en
P2093
Farbod Shojaei
Napoleone Ferrara
P304
P356
10.1016/J.DRUP.2008.09.001
P577
2008-10-23T00:00:00Z